Ponatinib promotes a G(1) cell-cycle arrest of merlin/NF2-deficient human schwann cells

Neurofibromatosis type 2 (NF2) is a genetic syndrome that predisposes individuals to multiple benign tumors of the central and peripheral nervous systems, including vestibular schwannomas. Currently, there are no FDA approved drug therapies for NF2. Loss of function of merlin encoded by the NF2 tumo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Petrilli, Alejandra M, Garcia, Jeanine, Bott, Marga, Plati, Stephani Klingeman, Dinh, Christine T, Bracho, Olena R, Yan, Denise, Zou, Bing, Mittal, Rahul, Telischi, Fred F, Liu, Xue-Zhong, Chang, Long-Sheng, Bradley, D Welling, Copik, Alicja J, Fernández-Valle, Cristina
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5458238/
https://ncbi.nlm.nih.gov/pubmed/28427224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15912
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados